⁇ First-Generation Antipsychotics: Your Brain's Classic Theater Troupe!

⁇ Welcome to the Original Antipsychotic Command Center!

Hey there, FGA monitoring expert! ⁇✨ Ready to meet your brain's classic theater troupe? First-Generation Antipsychotics (FGAs) are like having a team of experienced, old-school performers who know how to handle the toughest psychiatric shows - they're incredibly effective but require the expertise of a seasoned director to manage their dramatic tendencies! Think of this as your comprehensive guide to directing these powerful, classic performers! ⁇

FGA Reality Check! ⁇ These medications are like classic Broadway actors - incredibly talented and effective, but they come with more dramatic side effects than the newer generation, so they need careful direction and monitoring!

⁇ Meet Your Classic Theater Troupe

⁇ The Veteran Performers: "The Old-School Stars"

"We've been stopping psychosis since the 1950s - we know our craft!"

⁇ Haloperidol (Haldol): "The Powerhouse Leading Man" **(Drugs.com, 2019)**

"I'm the go-to star for severe psychosis and agitation!" - ⁇ **Superpower:** Potent antipsychotic effects, rapid action - ⁇ **Strengths:** Excellent for acute psychosis, available IV/IM - ⚠️ **Watch out for:** High EPS risk, tardive dyskinesia - ⁇ **Monitoring level:** Maximum maintenance required

⁇ Fluphenazine (Prolixin): "The Long-Acting Specialist" **(Siragusa et al., 2023)**

"I can work for weeks with just one injection!" - ⁇ **Superpower:** Long-acting depot

formulation - ** **Strengths:** Excellent compliance, sustained effect - ⚠️ **Watch out for:** EPS, tardive dyskinesia, injection site reactions - ** **Monitoring level:** High maintenance with movement monitoring

** Chlorpromazine (Thorazine): "The Original Pioneer" (Friedgood & Ripstein, 1955)

"I was the first antipsychotic - the grandfather of them all!" - ** **Superpower:** Historical significance, multiple effects - ** **Strengths:** Sedating, good for agitation - ⚠️ **Watch out for:** Sedation, hypotension, photosensitivity - ** **Monitoring level:** High maintenance veteran

⚡ Perphenazine (Trilafon): "The Balanced Performer" (Hartung et al., 2015)

"I offer good efficacy with moderate side effects!" - ** **Superpower:** Good balance of efficacy and tolerability - ** **Strengths:** Less sedating than chlorpromazine - ⚠️ **Watch out for:** EPS, tardive dyskinesia - ** **Monitoring level:** High maintenance

** Thiothixene (Navane): "The Focused Specialist" (Davis, 2007)

"I'm potent and focused on psychosis!" - ** **Superpower:** High potency, specific antipsychotic action - ** **Strengths:** Less sedation, good for positive symptoms - ⚠️ **Watch out for:** High EPS risk, movement disorders - ** **Monitoring level:** Maximum maintenance

** Loxapine (Loxitane): "The Versatile Character Actor"

"I have some unique properties among the classics!" - ** **Superpower:** Some serotonin activity, inhaled formulation - ** **Strengths:** Rapid-acting inhaled form available - ⚠️ **Watch out for:** Respiratory effects with inhaled form - ** **Monitoring level:** High maintenance with respiratory monitoring

** Visual FGA Monitoring Dashboard

```
   ** YOUR CLASSIC ANTIPSYCHOTIC COMMAND CENTER **

** MOVEMENT MONITOR ** CARDIAC SURVEILLANCE
EPS/Tardive Dyskinesia QTc/Arrhythmias
          | |
====================================
| |
| ** CLASSIC FGA HQ |
```

| (Your Veteran Troupe) |
| |
==========
| |
LIVER WATCH NMS ALERT SYSTEM
LFT Monitoring Temperature/Rigidity

Monitoring Intensity:
Moderate (Chlorpromazine) → Standard monitoring
High (Haloperidol) → ⚠️ Enhanced surveillance
Maximum (High-dose/Long-term) → Intensive monitoring

The FGA Monitoring Playbook

Baseline Assessment: "Pre-Performance Evaluation"

"Before our classic performers take the stage, we need a thorough

audition!"

Movement Disorder Baseline:

Neurological Assessment: - **Baseline AIMS:** Abnormal Involuntary Movement Scale - ♀ **Gait assessment:** Parkinsonian features - **Fine motor skills:** Tremor, rigidity evaluation - **Facial movements:** Baseline facial expressions

Movement History: - **Previous EPS:** History of movement disorders - **Prior antipsychotic exposure:** Previous tardive dyskinesia - **Family history:** Movement disorders, Parkinson's - **Age considerations:** Elderly higher risk

Cardiovascular Baseline:

Cardiac Assessment: - ⚡ **EKG baseline:** QTc measurement - **Blood pressure:** Baseline readings - **Heart rate:** Resting pulse - **Cardiac history:** Arrhythmias, structural disease
Cardiac Risk Factors: - **Age >65:** Increased cardiac risk - **Other QTc drugs:** Drug interaction assessment - ⚡ **Electrolyte status:** K+, Mg++, Ca++ levels - **Cardiac medications:** Interaction potential

Laboratory Baseline:

🩸 Liver Function: - **🩸 ALT, AST:** Baseline hepatic function - **🩸 Bilirubin:** Liver processing capacity - **🩸 Alkaline phosphatase:** Hepatic enzyme status - **🩸 Hepatotoxic medications:** Interaction assessment

🩸 Hematologic Baseline: - **🩸 CBC with differential:** Blood count baseline - **🩸 Blood dyscrasia history:** Previous hematologic issues - **🩸 Bone marrow suppressants:** Other medications

🩸 Ongoing Monitoring Schedule: "Performance Review Program"

🩸 Movement Disorder Monitoring: "The Choreography Watch"

🩸 AIMS Assessment Schedule: - **🩸 Baseline AIMS:** Before starting FGA - **🩸 3-month AIMS:** Early detection period - **🩸 6-month AIMS:** Standard monitoring - **🩸 Annual AIMS:** Long-term surveillance - **🩸 Symptom-driven:** If movement changes noted

🩸 What to Assess: - **🩸 Facial movements:** Lip smacking, tongue protrusion - **🩸 Extremity movements:** Finger movements, toe tapping - ♀ **Trunk movements:** Rocking, twisting - **🩸 Functional impact:** ADL interference

🩸 AIMS Scoring: - **🩸 0-1:** No abnormal movements - **🩸 2:** Minimal movements - **🩸 3-4:** Significant tardive dyskinesia

🩸 Cardiac Monitoring: "The Heart Rhythm Watch"

🩸 EKG Monitoring Schedule: - **🩸 Baseline EKG:** Before starting - **🩸 Dose dependent:** With significant increases - **🩸 Annual EKG:** Long-term monitoring - **🩸 Symptom-driven:** If cardiac symptoms

🩸 QTc Monitoring Thresholds: - **🩸 <450ms:** Safe range - **🩸 450-500ms:** Caution zone - **🩸 >500ms:** Dangerous - immediate action

🩸 Laboratory Monitoring: "The Biochemical Surveillance"

🩸 Liver Function Schedule: - **🩸 Baseline LFTs:** Before starting - **🩸 3-month LFTs:** Early monitoring - **🩸 Annual LFTs:** Long-term surveillance - **🩸 Symptom-driven:** If hepatic symptoms

🩸 Hematologic Monitoring: - **🩸 Baseline CBC:** Before starting - **🩸 Annual CBC:** Long-term monitoring - **🩸 Symptom-driven:** If infection, bleeding

🚨 Red Flag Alert System: "Emergency Protocols"

🚨 Movement Disorder Red Flags: "The Choreography Crisis Alarms"

🚨 Tardive Dyskinesia Emergency: **(Vasan & Padhy, 2023)**

🚨 New abnormal movements: - **🚨 Facial dyskinesia:** Lip smacking, tongue movements - **🚨 Limb dyskinesia:** Finger piano-playing, toe movements - ♀ **Trunk dyskinesia:** Rocking, pelvic movements - **🚨 Functional impairment:** Eating, speaking difficulties

🚨 Emergency Protocol: - **🚨 Immediate AIMS:** Document severity - **🚨 FGA discontinuation:** Consider immediate cessation - **🚨 Neurology referral:** Movement disorder specialist - **🚨 VMAT2 inhibitor:** Consider valbenazine, deutetrabenazine

🚨 Acute EPS Emergency:

⚡ **Acute dystonia:** - **Oculogyric crisis:** Eyes rolling upward - **🚨 Facial dystonia:** Jaw, tongue spasms - **🚨 Laryngeal dystonia:** Breathing difficulty - **🚨 Limb dystonia:** Muscle spasms

🚨 Emergency Treatment: - **🚨 Benztropine 1-2mg IM:** Immediate relief - **🚨 Diphenhydramine 25-50mg IM:** Alternative treatment - **🚨 Emergency evaluation:** If respiratory involvement - **🚨 Prophylactic anticholinergic:** Consider ongoing

Neuroleptic Malignant Syndrome (NMS): **(Simon et al., 2023)**

🚨 NMS Tetrad: - **Hyperthermia:** Fever >101°F - **🚨 Muscle rigidity:** Lead-pipe rigidity - **🚨 Mental status changes:** Confusion, coma - **🚨 Autonomic instability:** BP changes, diaphoresis

🚨 Emergency Protocol: - **🚨 Call 911 immediately:** Medical emergency - **🛑 Discontinue all antipsychotics:** Immediate cessation - **🏥 ICU admission:** Intensive monitoring required - **💊 Dantrolene/Bromocriptine:** Specific treatments

🫀 Cardiac Red Flags: "The Heart Emergency Alarms"

🫀 QTc Prolongation Emergency: **(Pourmand et al., 2017)**

⚡ QTc >500ms: - **🛑 Discontinue FGA:** Immediate cessation - **🫀 Cardiology referral:** Urgent consultation - **📊 Serial EKGs:** Monitor until normalization - **⚡ Electrolyte correction:** Optimize K+, Mg++

💓 New arrhythmias: - **🚨 Immediate EKG:** Document rhythm - **🫀 Cardiac evaluation:** Emergency assessment - **🛑 FGA discontinuation:** Consider immediate cessation - **🏥 Hospital evaluation:** If hemodynamically unstable

🫁 Hepatic Red Flags: "The Liver Emergency Alarms"

🫁 Hepatotoxicity Emergency:

🫁 ALT/AST >5x normal: - **🛑 Discontinue FGA:** Immediate cessation - **🫁 Hepatology referral:** Urgent consultation - **🩸 Comprehensive hepatic panel:** Full liver assessment - **🏥 Hospitalization consideration:** If severe

🫁 Jaundice development: - **🚨 Immediate FGA cessation:** Stop medication - **🩸 Urgent liver function:** Comprehensive testing - **🏥 Medical evaluation:** Rule out other causes - **🫁 Hepatitis screening:** Viral, autoimmune causes

🧠 FGA-Specific Monitoring Protocols

🧠 High-Potency FGAs (Haloperidol, Fluphenazine)

"The powerhouse performers with maximum EPS risk!"
🧠 Enhanced Movement Monitoring:

- **Monthly AIMS:** First 6 months
- **EPS assessment:** Every visit
- **Prophylactic anticholinergics:** Consider benztropine
- **Neurology consultation:** If movement disorders develop

Dose Optimization:

- **Start low:** 0.5-1mg haloperidol
- **Titrate slowly:** Weekly increases
- **Minimum effective dose:** Lowest dose for symptom control
- **Anticholinergic prophylaxis:** Especially in young males

Long-Acting Injectable FGAs

"The depot specialists requiring injection site monitoring!"

Injection Site Monitoring:

- **Site rotation:** Prevent tissue damage
- **Local reactions:** Swelling, pain, induration
- **Injection technique:** Proper Z-track method
- **Site assessment:** Each injection visit

Depot-Specific Schedule:

- **Injection frequency:** Every 4 weeks typically
- **Plasma level monitoring:** If available
- **Movement assessment:** Before each injection
- **Oral supplementation:** If needed initially

⚡ Low-Potency FGAs (Chlorpromazine)

"The sedating performers with anticholinergic effects!"
⚡ Enhanced Cardiovascular Monitoring:

- **⚡ Orthostatic vitals:** Every visit
- **⚡ Cardiac assessment:** Enhanced monitoring
- **⚡ Anticholinergic burden:** Total medication assessment
- **⚡ Elderly considerations:** Increased sensitivity

☀️ Photosensitivity Monitoring:

- **☀️ Sun exposure education:** Protective measures
- **⚡ Sunscreen recommendations:** High SPF required
- **Skin assessment:** Monitor for changes
- **☀️ Seasonal considerations:** Summer precautions

⚡ Pro Tips for FGA Monitoring Mastery

⚡ Clinical Pearls:

⚡ Movement monitoring is critical: AIMS every 6 months minimum **⚡ Start low, go slow:** Especially with high-potency FGAs **NMS is a medical emergency:** High index of suspicion **⚡ Cardiac monitoring prevents tragedies:** QTc surveillance essential

Patient/Family Communication:

⚡ Movement Education: - **"We'll watch carefully for any unusual movements"** - **"Report any new muscle stiffness or movements immediately"** - **"These medications are very effective but need careful monitoring"** - **"Call immediately if you develop fever with muscle stiffness"**

⚙️ Technology Integration:

⚙️ AIMS scoring apps: Standardized movement assessment **⚙️ EKG monitoring:** QTc calculation tools **Temperature tracking:** NMS early detection **⚙️ Medication adherence:** Depot injection reminders

⚙️ The Bottom Line: Your FGA Monitoring Superpower!

⚙️ Key Takeaways:

1. **⚙️ FGAs are classic powerhouses:** Highly effective but require expert monitoring
2. **⚙️ Movement monitoring is essential:** Tardive dyskinesia prevention critical 3. **NMS is a medical emergency:** High mortality if not recognized 4. **⚙️ Cardiac effects are significant:** QTc monitoring prevents tragedies 5. **⚙️ Risk-benefit assessment is key:** Use when benefits outweigh risks

⚙️ Your FGA Monitoring Superpowers:

♀ **Movement detective:** Monitor for EPS and tardive dyskinesia **NMS recognizer:** Identify this medical emergency early **⚙️ Cardiac guardian:** Monitor heart rhythm and function **⚙️ Laboratory interpreter:** Track liver and blood effects **⚙️ Classic medication master:** Safely use these powerful veterans

⚙️ Remember:

FGAs are like classic Broadway performers - incredibly talented and effective, but they require an experienced director who knows how to manage their dramatic tendencies! With proper monitoring, these medications can be life-saving for severe psychosis and treatment-resistant cases. Master FGA monitoring, and you'll have access to some of psychiatry's most powerful classic tools! ⚙️✨

Your patients' movements and hearts are constantly responding to these powerful medications - now you know how to monitor them safely for optimal classic

performance! ��

Ready to explore MAOI monitoring next? Let's dive into the most complex antidepressant surveillance! ��

References

Davis, C. (2007). Thiothixene. *Elsevier EBooks*, 1–6. https://doi.org/10.1016/b978-008055232-3.62750-3

Drugs.com. (2019). *Haloperidol*. Drugs.com; Drugs.com. https://www.drugs.com/mtm/haloperidol.html

Friedgood, C. E., & Ripstein, C. B. (1955). Chlorpromazine (thorazine) in the treatment of intractable hiccups. *Journal of the American Medical Association*, *157*(4), 309–310. https://doi.org/10.1001/jama.1955.02950210005002

Hartung, B., Sampson, S., & Leucht, S. (2015). Perphenazine for schizophrenia. *Cochrane Database of Systematic Reviews*. https://doi.org/10.1002/14651858.cd003443.pub3

Pourmand, A., Mazer-Amirshahi, M., Chistov, S., Sabha, Y., Vukomanovic, D., & Almulhim, M. (2017). Emergency department approach to QTc prolongation. *The American Journal of Emergency Medicine*, *35*(12), 1928–1933. https://doi.org/10.1016/j.ajem.2017.08.044

Simon, L. V., Hashmi, M. F., & Callahan, A. L. (2023, April 24). *Neuroleptic Malignant*

Syndrome. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482282/

Siragusa, S., Bistas, K. G., & Saadabadi, A. (2023, May 23). *Fluphenazine*. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459194/

Vasan, S., & Padhy, R. K. (2023, April 24). *Tardive Dyskinesia*. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK448207/